#5 - Pfizer (NYSE:PFE)
Pfizer (NYSE:PFE) is one of the leading names in the race for a Covid-19 vaccine. One of the reasons that Pfizer is considered to be a favorite is because, unlike some of the small biotech companies involved in Operation Warp Speed, Pfizer has a long, proven track record of products in the market.
Here’s a simple reality. Most of the names you’re reading about today will not be able to deliver a safe, effective vaccine. And when they can’t their companies will go back to being in relative anonymity. That’s not the case with Pfizer.
Late last year, Pfizer had a whopping 24 programs in Phase 3 of clinical trials. Undoubtedly the progress of some of these candidates may have been delayed due to the pandemic. But if just a few make it to market, it will be big news for Pfizer.
In the trailing twelve months ending in June of this year, Pfizer had $1.26 billion in free cash flow. The company’s debt-to-equity ratio is 0.78%. Plus among the company’s in this presentation, Pfizer sports one of the best dividends with a yield of just over 4% as of this writing.
About Pfizer
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Read More - Current Price
- $25.65
- Consensus Rating
- Moderate Buy
- Ratings Breakdown
- 7 Buy Ratings, 8 Hold Ratings, 1 Sell Ratings.
- Consensus Price Target
- $32.92 (28.4% Upside)
